NYSE:DNA Ginkgo Bioworks (DNA) Stock Price, News & Analysis $10.30 +1.72 (+20.07%) Closing price 03:59 PM EasternExtended Trading$10.22 -0.09 (-0.83%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ginkgo Bioworks Stock (NYSE:DNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ginkgo Bioworks alerts:Sign Up Key Stats Today's Range$8.44▼$10.4450-Day Range$6.51▼$9.4152-Week Range$5.37▼$17.58Volume4.02 million shsAverage Volume1.21 million shsMarket Capitalization$693.74 millionP/E RatioN/ADividend YieldN/APrice Target$6.33Consensus RatingReduce Company Overview Ginkgo Bioworks is a biotechnology company that develops and operates a platform for programming cells. Its technology combines biological engineering, automation, software and data science to help customers design, build and test microorganisms and other biological systems for commercial applications. The company provides cell-programming services and related tools to customers in areas including pharmaceuticals, agriculture, food and ingredients, industrial chemicals, materials and consumer products. Ginkgo also supports biosecurity initiatives, including systems intended to monitor biological threats and accelerate the development of diagnostics, vaccines and other responses. Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che and Tom Knight. The company is headquartered in Boston and serves customers and partners across multiple industries and geographies. It became a publicly traded company on the New York Stock Exchange in 2021 under the symbol DNA.AI Generated. May Contain Errors. Read More Ginkgo Bioworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreDNA MarketRank™: Ginkgo Bioworks scored higher than 23% of companies evaluated by MarketBeat, and ranked 767th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingReduce Consensus RatingGinkgo Bioworks has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 2 sell ratings.Downside RiskGinkgo Bioworks has a consensus price target of $6.33, representing about 38.5% downside from its current price of $10.30.Amount of Analyst CoverageGinkgo Bioworks has only been the subject of 4 research reports in the past 90 days.Read more about Ginkgo Bioworks' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ginkgo Bioworks are expected to grow in the coming year, from ($3.20) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ginkgo Bioworks is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ginkgo Bioworks is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGinkgo Bioworks has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ginkgo Bioworks' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.19% of the float of Ginkgo Bioworks has been sold short.Short Interest Ratio / Days to CoverGinkgo Bioworks has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Ginkgo Bioworks has recently increased by 4.39%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGinkgo Bioworks does not currently pay a dividend.Dividend GrowthGinkgo Bioworks does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.47 News SentimentGinkgo Bioworks has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ginkgo Bioworks this week, compared to 2 articles on an average week.Search Interest4 people have searched for DNA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,703.00 in company stock.Percentage Held by Insiders12.69% of the stock of Ginkgo Bioworks is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ginkgo Bioworks' insider trading history. Receive DNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNA Stock News HeadlinesGinkgo Bioworks Holdings Inc.September 20, 2026 | barrons.comGinkgo Bioworks (NYSE:DNA) Director Sells 5,000 SharesSeptember 17, 2026 | insidertrades.comShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.September 24 at 1:00 AM | Digest Publishing (Ad)Head-To-Head Contrast: Revvity (NYSE:RVTY) vs. Ginkgo Bioworks (NYSE:DNA)September 17, 2026 | americanbankingnews.comGinkgo Bioworks Holdings consensus price target cut by 22.22% to $7.14September 16, 2026 | msn.comGinkgo Datapoints Partners With Lilly TuneLab To Link AI Models And Lab DataSeptember 16, 2026 | rttnews.comGinkgo Datapoints to Supply Discovery Data for Eli Lilly's TuneLab NetworkSeptember 16, 2026 | finance.yahoo.comTwist Bio, and Gingko rise after agreements with Lilly TuneLabSeptember 16, 2026 | seekingalpha.comSee More Headlines DNA Stock Analysis - Frequently Asked Questions How have DNA shares performed this year? Ginkgo Bioworks' stock was trading at $8.27 at the beginning of the year. Since then, DNA shares have increased by 24.6% and is now trading at $10.3020. How were Ginkgo Bioworks' earnings last quarter? Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.15. The firm earned $20.16 million during the quarter, compared to the consensus estimate of $24.05 million. Ginkgo Bioworks had a negative trailing twelve-month return on equity of 60.27% and a negative net margin of 259.96%. Read the conference call transcript. Who are Ginkgo Bioworks' major shareholders? Ginkgo Bioworks' top institutional shareholders include Balance Capital Partners L.P. (0.30%), California State Teachers Retirement System (0.08%), AXQ Capital LP (0.04%) and Squarepoint Ops LLC (0.02%). Insiders that own company stock include Marijn E Dekkers, Mark E Dmytruk, Harry Sloan, Barry Canton, Reshma P Shetty, Jason R Kelly, Steven P Coen and Christian O Henry. View institutional ownership trends. How do I buy shares of Ginkgo Bioworks? Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ginkgo Bioworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Enovix (ENVX), Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Compass Pathways (CMPS), Rambus (RMBS), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings8/05/2026Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DNA's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:DNA CIK1830214 Webwww.ginkgobioworks.com Phone877-442-5362FaxN/AEmployees485Year Founded2020Price Target and Rating Average Price Target for Ginkgo Bioworks$6.33 High Price Target$9.00 Low Price Target$5.00 Potential Upside/Downside-38.5%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$312.76 million Net Margins-259.96% Pretax Margin-277.33% Return on Equity-60.27% Return on Assets-26.88% Debt Debt-to-Equity RatioN/A Current Ratio4.57 Quick Ratio4.57 Sales & Book Value Annual Sales$132.42 million Price / Sales5.24 Cash FlowN/A Price / Cash FlowN/A Book Value$8.74 per share Price / Book1.18Miscellaneous Outstanding Shares67,340,000Free Float58,795,000Market Cap$693.74 million OptionableOptionable Beta1.76 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:DNA) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
